What results from LEADER, showing CV risk reduction with liraglutide, do you think are most important and how are they likely to change our use of GLP-1 RAs in high risk patients with T2D?

What results from LEADER, showing CV risk reduction with liraglutide, do you think are most important and how are they likely to change our use of GLP-1 RAs in high risk patients with T2D?

What results from LEADER, showing CV risk reduction with liraglutide, do you think are most important and how are they likely to change our use of GLP-1 RAs in high risk patients with T2D?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Robert Henry, MD

Robert Henry, MD

Chief, Center for Metabolic Research
Chief, Section of Endocrinology, Metabolism & Diabetes
Veterans Affairs Healthcare System
Professor of Medicine‚ Department of Medicine
Division of Endocrinology and Metabolism
University of California‚ San Diego